Cytotoxicity and cellular accumulation of a new cis-diammineplatinum (II) complex containing procaine in murine L1210 cells sensitive and resistant to cis-diamminedichloroplatinum (II).
The emergence of drug resistance during tumor chemotherapy is one of the main problems associated with cancer treatment, particularly with cisplatin (cis-DDP). In the hope of overcoming this problem, various cis-DDP-derived compounds have been synthesized, and their pharmacological activity was compared with that of cis-DDP. In this paper we report on studies on the cytotoxic activity induced by cis-diamminechloro-[2-(diethylamino)ethyl-4-aminobenzoate, N4]- chlorideplatinum(II) monohydrochloride monohydrate (DPR), a new complex of platinum containing procaine. All experiments were carried out on murine leukemic cells, which were either sensitive (L1210) or resistant (L1210/DDP) to cis-DDP. A tetrazolium dye (MTT) assay conducted 5 days after a 2-h exposure of cells to both drugs was utilized to determine the resistance factor (RF) of L1210/DDP cells as compared with the sensitive wild-type cells. Drug accumulation and efflux, together with the amount of platinum bound to DNA, were also investigated. The activity of DPR on sensitive cells was not significantly different from that of cis-DDP. Conversely, DPR was 4.3 times more effective than cis-DDP on resistant cells. A decreased drug accumulation is one of the mechanisms of resistance to cis-DDP of L1210/DDP cells. However, DPR accumulation was not significantly different in sensitive and resistant L1210 cells. Under culture conditions that yielded similar intracellular platinum concentrations, treatment with DPR produced significantly greater DNA platination than did treatment with cis-DDP in both cell lines. No difference in efflux was observed between L1210 and L1210/DDP cells exposed to either cis-DDP or DPR. Our results show that in parental cells, DPR is as potent as cis-DDP on a molar basis, and it is also minimally cross-resistant with cis-DDP in L1210/DDP cells. A direct implication of our results is that DPR could be useful in those human tumors showing a mechanism of resistance similar to that of L1210/DDP cells.
Viale
M
M
Istituto Nazionale per la Ricerca sul Cancro, Laboratorio Farmacologia Tossicologica, Genova, Italy.
Cafaggi
S
S
Parodi
B
B
Esposito
M
M
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000378:metabolism / Q000633:toxicity*; D048429:Cell Size / Q000187:drug effects; D002945:Cisplatin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000633:toxicity*; D004247:DNA / Q000378:metabolism; D007939:Leukemia L1210 / Q000378:metabolism / Q000473:pathology; D051379:Mice; D009944:Organoplatinum Compounds / Q000737:chemistry / Q000378:metabolism / Q000633:toxicity*; D010984:Platinum / Q000378:metabolism; D011343:Procaine / Q000031:analogs & derivatives* / Q000737:chemistry* / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity; D013054:Spectrophotometry, Atomic; D013329:Structure-Activity Relationship; D013778:Tetrazolium Salts / Q000737:chemistry; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D013778:Tetrazolium Salts; C080075:cisplatin-procaine complex; C042207:4-anisyltetrazolium blue; D010984:Platinum; D011343:Procaine; D004247:DNA; D002945:Cisplatin